Report
Jake Strole
EUR 850.00 For Business Accounts Only

Morningstar | Masimo Continues to Gain Market Share, Supporting its Positive Moat Trend Rating

Masimo has established itself at the forefront of algorithms and sensor technologies for patient monitoring through the development of its proprietary signal extraction technology, or SET, for use in pulse oximetry and other measurement applications. The SET platform remains leagues ahead of competing products in terms of accuracy and reliability, leading to extremely sticky customer relationships and meaningful pricing power. Masimo has developed a hybrid go-to-market model that has allowed for the proliferation of its SET and next-generation rainbow SET measurement parameters through direct sales of Masimo monitors and through third-party OEM partners. The company leverages this installed base to drive utilization of its reusable and disposable sensors, which represent high-margin recurring revenue. This strategy has generated returns on invested capital substantially ahead of weighted average cost of capital each year since the 2007 initial public offering, and we believe ROIC is poised to rise higher over our forecast period. Management has transitioned from an infrastructure buildout mentality to one of measured investment, and the financials have begun to show improved leverage. Further, the recent settlement and joint venture agreement with Philips represents, in our view, one of the most significant milestones in the company’s history. While the partnership is still in its early days, we think the long-term outlook for Masimo is exceedingly bright.We view the company as having built a narrow moat for itself in patient monitoring through strong intangible assets protected by patents and proprietary trade secrets, as well as switching costs that have been embedded in its installed base. A strong top-down push to integrate Masimo sensor technology in Philips’ leading line of patient monitors will expand Masimo’s share of the installed base while upgrading customers to the company’s next-generation rainbow SET. This should help to not only better protect its intangibles-based moat source, but also raise the bar for competitors looking to catch up.
Underlying
Masimo Corporation

Masimo is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. The company provides its products to hospitals, emergency medical service providers, long-term care facilities, physician offices, veterinarians and consumers. The company's main business is Measure-through Motion and Low Perfusion? pulse oximetry monitoring, known as Masimo Signal Extraction Technology? pulse oximetry. The company's products offerings also includes noninvasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Jake Strole

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch